← Back to Search
Cyclosporine A-Nanosuspension: Formulation, Characterization And In Vivo Comparison With A Marketed Formulation
M. Nakarani, P. Patel, J. Patel, P. Patel, R. Murthy, Subhash S. Vaghani
Published 2010 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.
This paper references
Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A.
D. Verma (2004)
Oral administration of liposomes containing cyclosporine: a pharmacokinetic study
M. Al-Meshal (1998)
Targeted and Controlled Drug Delivery, Novel Carrier Systems. 1 ed
SP Vyas (2002)
Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
F. Lai (2009)
Formulation, Characterization and In Vivo Comparison with … 361 Sci Pharm
A Cyclosporine (2010)
The effect of particle size distribution on dissolution rate and oral absorption
R. J. Hintz (1989)
Adv. Drug Delivery Rev.
F. Welt (1997)
Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles.
R. H. Muller (2004)
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.
C. Keck (2006)
Nanocrystal technology, drug delivery and clinical applications
Jens-Uwe A. H. Junghanns (2008)
Formulation, Characterization and In Vivo Comparison with … 359 Sci Pharm
A Cyclosporine (2010)
Cyclosporin-containing pharmaceutical composition
Jw Kim (1999)
Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles.
M. Lee (1999)
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards
R. LÃ¶benberg (2000)
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
C. Jacobs (2004)
Pharmacokinetic behavior of Cyclosporine A in rabbits by oral administration of lecithin vesicle and sandimmune neoral
J Guo (2001)
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
Nanosuspension: Formulation, Characterization and In Vivo Comparison with … 361
Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer.
W. Lee (2002)
Therapeutic applications of colloidal drug carriers.
Targeted and Controlled Drug Delivery
S P Vyas (2002)
Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral.
J. Guo (2001)
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.
J. Dressman (2000)
Pharmaceutical Statistics: Practical and Clinical Applications
M. Montagne (1985)
Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
G. Liversidge (1995)
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
Characterization of 5-fluorouracil microspheres for colonic drug
Z Rahman (2006)
Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique
R. Mueller (1998)
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
K. Peters (2000)
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards.
R. Löbenberg (2000)
Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process.
J. Jaiswal (2004)
Controlled drug delivery with nanoparticles : current possibilities and future trends
P. Couvreur (1995)
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
Handbook of Pharmaceutical Excipients
Pharmaceutical Press (2012)
Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.
R. Mueller (2002)
An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine
B. Johnson (2008)
Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects.
J. Wong (2008)
Targeted and Controlled Drug Delivery: Novel Carrier Systems
A. Florence (2003)
Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs.
Int J Pharm
New Delhi: CBS Publishers
Nanosuspension: Formulation, Characterization and In Vivo Comparison with … 359
This paper is referenced by
DESIGN AND EVALUATION OF SOLID LIPID NANOPARTICLES OF TAMOXIFEN CITRATE BY FACTORIAL DESIGN
B. Basu (2012)
Drug nanocrystals in the commercial pharmaceutical development process.
J. Möschwitzer (2013)
Nanosuspension – A Novel Carrier For Lipidic Drug Transfer
Abhyangshree Nandkumar Mane (2014)
Nanosuspensions: a new approach for organ and cellular targeting in infectious diseases
Shegokar Ranjita (2013)
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
Shantanu S Balkundi (2011)
Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor.
M. Talekar (2012)
Stability of nanosuspensions in drug delivery.
Y. Wang (2013)
Nanosuspension: An Assuring Novel Drug Delivery System
S. Das (2013)
Formulation, optimization, and in vitro/in vivo evaluation of furosemide nanosuspension for enhancement of its oral bioavailability
B. Sahu (2014)
NANOSUSPENSION : BIOAVAILABILITY ENHANCING NOVEL APPROACH
B. S. Nayak (2018)
Drug Delivery Using Nanocarriers: Indian Perspective
S. Gupta (2012)
Preparation and Characterization of Ursodeoxycholic Acid Nanosuspension
Peng-fei Yue (2012)
Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis
J. Patel (2014)
Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles
S. Leung (2016)
Enhancing effect of negative polypropylene electret on in vitro transdermal delivery of cyclosporine A solution and its synergistic effect with ethyl oleate
Cui Longjiu (2013)
Associating Drugs with Polymer Nanoparticles: A Challenge
C. Zandanel (2016)
Preparation and characterization of a lutein loading nanoemulsion system for ophthalmic eye drops
Chaemin Lim (2016)
A New Emerging Technique for Biovailability Enhancement
Bhatt Ganesh (2013)
Pharmacological screening of self-emulsifying drug delivery system containing cyclosporine for solubility enhancement
Ashok Kumar Rajpoot (2019)
Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method.
Boontida Morakul (2014)
NANOSUSPENSION OF A DRUG AND ITS BIOLOGICAL ACTIVITY- A REVIEW
S. Nair (2016)
Drug Delivery by Polymer Nanoparticles: The Challenge of Controlled Release and Evaluation
C. Charrueau (2016)
FORMULATION OF NANOSUSPENSION AND NANOEMULSION AS A NEW APPROACHFOR THE DELIVERY OF POORLY SOLUBLE DRUGS
O. Bhusnure (2015)
Application of Acoustic- Vibratory Milling For Screening and Scale-Up of Micro/ Nanosuspensions in Early Drug Discovery and Development
Hoang D. Lu (2018)
Effect of hydrophobic nanoparticle cores on the characteristics of poly ( ε-caprolactone )-cod-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles loaded with camptothecin
Y. Sirithananchai (2015)
NANOSUSPENSION: A NOVEL APPROACH TOWARDS THE DRUG DELIVERY SYSTEM
Shailesh U. Ginoya (2013)
Formulation and Optimization of Nanosuspension Prepared By Media Milling Technique to Enhance the Solubility of Isradipine
Umang Motka (2017)
FORMULATION AND EVALUATION OF POLYMERIC NANOSUSPENSION OF NARINGENIN
R. Sumathi (2017)
Nanosuspension Technologies for Delivery of Drugs
Sachin S.Pawar (2017)
Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation.
S. Yadav (2015)
Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System.
Daniel J. Trepanier (2018)
Formulation and Evaluation of Nanosuspension Formulation for Drug Delivery of Simvastatin
Rupali L. Shid (2014)See more